Perspective Therapeutics (NASDAQ:CATX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Perspective Therapeutics (NASDAQ:CATX) have been assigned an average rating of “Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $11.8571.

A number of equities research analysts recently issued reports on the company. Piper Sandler assumed coverage on Perspective Therapeutics in a research note on Thursday. They issued an “overweight” rating and a $16.00 price objective on the stock. UBS Group lowered their price target on shares of Perspective Therapeutics from $18.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, November 21st. B. Riley Financial dropped their price target on shares of Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research note on Monday, November 24th. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Wedbush reissued an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Friday, January 30th.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $5.60 on Tuesday. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $6.16. The company has a fifty day moving average price of $3.48. The company has a market capitalization of $416.29 million, a price-to-earnings ratio of -6.22 and a beta of 1.75.

Institutional Trading of Perspective Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CATX. Aigen Investment Management LP purchased a new position in Perspective Therapeutics during the 4th quarter valued at about $28,000. nVerses Capital LLC bought a new position in shares of Perspective Therapeutics in the fourth quarter valued at approximately $31,000. AXQ Capital LP grew its stake in Perspective Therapeutics by 24.2% during the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after acquiring an additional 2,481 shares in the last quarter. Engineers Gate Manager LP bought a new stake in Perspective Therapeutics during the 4th quarter worth approximately $35,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Perspective Therapeutics in the 4th quarter worth approximately $42,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.